JEIL PHARMACEUTICAL CO., LTD.
🇰🇷South Korea
The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04914221
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
A Study of Lubiprostone to Treat Constipation
Recruiting
- Conditions
- Constipation
- Interventions
- Other: No Intervention
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 3000
- Registration Number
- NCT04861233
- Locations
- 🇰🇷
Dongguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Adult Volunteers Volunteers
Phase 1
Completed
- Conditions
- Hypertension With Dyslipidemia
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT03707899
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.
Phase 1
Completed
- Conditions
- HyperlipidemiasDiabetes
- Interventions
- Drug: "Metformin" and "Rosuvastatin" seperately
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03690778
- Locations
- 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Device: UNI-DEB
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2018-06-21
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03564405
- Locations
- 🇰🇷
Catholic University Seoul St. Mary Hospital, Seoul, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Device: UNI-DEB
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 62
- Registration Number
- NCT03533920
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Gyeonggi-do, Korea, Republic of
Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Hypertension With Hyperlipidemia
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03461081
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Anti-Ulcer Agents
- Interventions
- Drug: Cohort 5 (JP-1366 E mg)Drug: Cohort 9 (JP-1366 I mg)Drug: Cohort 2 (JP-1366 B mg)Drug: Cohort 4 (JP-1366 D mg)Drug: Cohort 6 (JP-1366 F mg)Drug: Cohort 8 (JP-1366 H mg)Drug: Cohort 1 (JP-1366 A mg)Drug: Cohort 3 (JP-1366 C mg)Drug: Cohort 7 (JP-1366 G mg)
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 115
- Registration Number
- NCT03383042
- Locations
- 🇰🇷
Seoul National University Hospital(SNUH), Seoul, Jongno-Gu, Korea, Republic of
Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects.
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT03362008
- Locations
- 🇰🇷
Inha University Hospital, Incheon, Korea, Republic of
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers
Phase 1
Completed
- Conditions
- Hypertension With Dyslipidemia
- Interventions
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03247140
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of